Zoetis Inc. (NYSE:ZTS) Shares Acquired by Outlook Wealth Advisors LLC

Outlook Wealth Advisors LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 66.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,371 shares of the company’s stock after acquiring an additional 2,153 shares during the period. Outlook Wealth Advisors LLC’s holdings in Zoetis were worth $875,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Pensionfund Sabic grew its holdings in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares during the last quarter. PFW Advisors LLC purchased a new position in Zoetis in the 4th quarter worth about $1,764,000. JPMorgan Chase & Co. raised its holdings in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the period. Simplify Asset Management Inc. purchased a new stake in Zoetis during the third quarter valued at about $11,684,000. Finally, B&L Asset Management LLC acquired a new position in shares of Zoetis in the third quarter worth about $563,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 1.7 %

Shares of NYSE:ZTS opened at $167.23 on Thursday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a fifty day moving average price of $171.31 and a 200 day moving average price of $180.16. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $75.45 billion, a PE ratio of 31.43, a P/E/G ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the company posted $1.36 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s payout ratio is presently 32.52%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZTS shares. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.